Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins
- Autores
- Sanmamed, Miguel F.; Carranza Rua, Omar; Alfaro, Carlos; Oñate, Carmen; Martín Algarra, Salvador; Perez, Guiomar; Landazuri, Sara F.; Gonzalez, Alvaro; Gross, Stefanie; Rodriguez, Inmaculada; Muñoz Calleja, Cecilia; Rodríguez Ruiz, María; Sangro, Bruno; López Picazo, José M.; Rizzo, Manglio Miguel; Mazzolini Rizzo, Guillermo Daniel; Pascual, Juan I.; Andueza, Maria Pilar; Perez Gracia, Jose Luis; Melero, Ignacio
- Año de publicación
- 2014
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Purpose: Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. It exerts various functions in shaping protumoral vascularization and inflammation/immunity. We evaluated sequential levels of serum IL8 in preclinical tumor models and in patients to assess its ability to estimate tumor burden. Experimental Design: IL8 levelsweremonitored by sandwich ELISAs incultured tumor cells supernatants, tumor-xenograftedmice serum, and in samples from126 patients with cancer. Wecorrelated IL8 serumlevels with baseline tumor burden and with treatment-induced changes in tumor burden, as well as with prognosis. Results: IL8 concentrations correlated with the number of IL8-producing tumor cells in culture. In xenografted neoplasms, IL8 serum levels rapidly dropped after surgical excision, indicating an accurate correlation with tumor burden. In patients with melanoma (n = 16), renal cell carcinoma (RCC; n = 23), non-small cell lung cancer (NSCLC; n = 21), or hepatocellular carcinoma (HCC; n = 30), serum IL8 concentrations correlated with tumor burden and stage, survival (melanoma, n = 16; RCC, n = 23; HCC, n = 33), and objective responses to therapy, including those to BRAF inhibitors (melanoma, n = 16) and immunomodulatory monoclonal antibodies (melanoma, n = 8). IL8 concentrations in urine (n = 18) were mainly elevated in tumors with direct contact with the urinary tract. Conclusions: IL8 levels correlate with tumor burden in preclinical models and in patients with cancer. IL8 is a potentially useful biomarker to monitor changes in tumor burden following anticancer therapy, and has prognostic significance.
Fil: Sanmamed, Miguel F.. Universidad de Navarra; España
Fil: Carranza Rua, Omar. Universidad de Navarra; España
Fil: Alfaro, Carlos. Universidad de Navarra; España
Fil: Oñate, Carmen. Universidad de Navarra; España
Fil: Martín Algarra, Salvador. Universidad de Navarra; España
Fil: Perez, Guiomar. Universidad de Navarra; España
Fil: Landazuri, Sara F.. Universidad de Navarra; España
Fil: Gonzalez, Alvaro. Universidad de Navarra; España
Fil: Gross, Stefanie. University Hospital Erlangen; Alemania
Fil: Rodriguez, Inmaculada. Universidad de Navarra; España
Fil: Muñoz Calleja, Cecilia. Universidad Autonoma de Madrid. Hospital Universitario de la Princesa; España
Fil: Rodríguez Ruiz, María. Universidad de Navarra; España
Fil: Sangro, Bruno. Universidad de Navarra; España
Fil: López Picazo, José M.. Universidad de Navarra; España
Fil: Rizzo, Manglio Miguel. Universidad Austral. Facultad de Ciencias Biomédicas. Laboratorio de Terapia Genética; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Laboratorio de Terapia Genética; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pascual, Juan I.. Universidad de Navarra; España
Fil: Andueza, Maria Pilar. Universidad de Navarra; España
Fil: Perez Gracia, Jose Luis. Universidad de Navarra; España
Fil: Melero, Ignacio. Universidad de Navarra; España - Materia
-
Il-8
Cancer
Serum Levels
Prognosis - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/37046
Ver los metadatos del registro completo
id |
CONICETDig_e58df1facff8683e3f024d1fcac99cf8 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/37046 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue originsSanmamed, Miguel F.Carranza Rua, OmarAlfaro, CarlosOñate, CarmenMartín Algarra, SalvadorPerez, GuiomarLandazuri, Sara F.Gonzalez, AlvaroGross, StefanieRodriguez, InmaculadaMuñoz Calleja, CeciliaRodríguez Ruiz, MaríaSangro, BrunoLópez Picazo, José M.Rizzo, Manglio MiguelMazzolini Rizzo, Guillermo DanielPascual, Juan I.Andueza, Maria PilarPerez Gracia, Jose LuisMelero, IgnacioIl-8CancerSerum LevelsPrognosishttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Purpose: Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. It exerts various functions in shaping protumoral vascularization and inflammation/immunity. We evaluated sequential levels of serum IL8 in preclinical tumor models and in patients to assess its ability to estimate tumor burden. Experimental Design: IL8 levelsweremonitored by sandwich ELISAs incultured tumor cells supernatants, tumor-xenograftedmice serum, and in samples from126 patients with cancer. Wecorrelated IL8 serumlevels with baseline tumor burden and with treatment-induced changes in tumor burden, as well as with prognosis. Results: IL8 concentrations correlated with the number of IL8-producing tumor cells in culture. In xenografted neoplasms, IL8 serum levels rapidly dropped after surgical excision, indicating an accurate correlation with tumor burden. In patients with melanoma (n = 16), renal cell carcinoma (RCC; n = 23), non-small cell lung cancer (NSCLC; n = 21), or hepatocellular carcinoma (HCC; n = 30), serum IL8 concentrations correlated with tumor burden and stage, survival (melanoma, n = 16; RCC, n = 23; HCC, n = 33), and objective responses to therapy, including those to BRAF inhibitors (melanoma, n = 16) and immunomodulatory monoclonal antibodies (melanoma, n = 8). IL8 concentrations in urine (n = 18) were mainly elevated in tumors with direct contact with the urinary tract. Conclusions: IL8 levels correlate with tumor burden in preclinical models and in patients with cancer. IL8 is a potentially useful biomarker to monitor changes in tumor burden following anticancer therapy, and has prognostic significance.Fil: Sanmamed, Miguel F.. Universidad de Navarra; EspañaFil: Carranza Rua, Omar. Universidad de Navarra; EspañaFil: Alfaro, Carlos. Universidad de Navarra; EspañaFil: Oñate, Carmen. Universidad de Navarra; EspañaFil: Martín Algarra, Salvador. Universidad de Navarra; EspañaFil: Perez, Guiomar. Universidad de Navarra; EspañaFil: Landazuri, Sara F.. Universidad de Navarra; EspañaFil: Gonzalez, Alvaro. Universidad de Navarra; EspañaFil: Gross, Stefanie. University Hospital Erlangen; AlemaniaFil: Rodriguez, Inmaculada. Universidad de Navarra; EspañaFil: Muñoz Calleja, Cecilia. Universidad Autonoma de Madrid. Hospital Universitario de la Princesa; EspañaFil: Rodríguez Ruiz, María. Universidad de Navarra; EspañaFil: Sangro, Bruno. Universidad de Navarra; EspañaFil: López Picazo, José M.. Universidad de Navarra; EspañaFil: Rizzo, Manglio Miguel. Universidad Austral. Facultad de Ciencias Biomédicas. Laboratorio de Terapia Genética; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Laboratorio de Terapia Genética; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Pascual, Juan I.. Universidad de Navarra; EspañaFil: Andueza, Maria Pilar. Universidad de Navarra; EspañaFil: Perez Gracia, Jose Luis. Universidad de Navarra; EspañaFil: Melero, Ignacio. Universidad de Navarra; EspañaAmerican Association for Cancer Research2014-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/mswordapplication/pdfhttp://hdl.handle.net/11336/37046Sanmamed, Miguel F.; Carranza Rua, Omar; Alfaro, Carlos; Oñate, Carmen; Martín Algarra, Salvador; et al.; Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins; American Association for Cancer Research; Clinical Cancer Research; 20; 22; 11-2014; 5697-57071078-0432CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://clincancerres.aacrjournals.org/content/20/22/5697.longinfo:eu-repo/semantics/altIdentifier/doi/10.1158/1078-0432.CCR-13-3203info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:49:33Zoai:ri.conicet.gov.ar:11336/37046instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:49:33.465CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins |
title |
Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins |
spellingShingle |
Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins Sanmamed, Miguel F. Il-8 Cancer Serum Levels Prognosis |
title_short |
Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins |
title_full |
Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins |
title_fullStr |
Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins |
title_full_unstemmed |
Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins |
title_sort |
Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins |
dc.creator.none.fl_str_mv |
Sanmamed, Miguel F. Carranza Rua, Omar Alfaro, Carlos Oñate, Carmen Martín Algarra, Salvador Perez, Guiomar Landazuri, Sara F. Gonzalez, Alvaro Gross, Stefanie Rodriguez, Inmaculada Muñoz Calleja, Cecilia Rodríguez Ruiz, María Sangro, Bruno López Picazo, José M. Rizzo, Manglio Miguel Mazzolini Rizzo, Guillermo Daniel Pascual, Juan I. Andueza, Maria Pilar Perez Gracia, Jose Luis Melero, Ignacio |
author |
Sanmamed, Miguel F. |
author_facet |
Sanmamed, Miguel F. Carranza Rua, Omar Alfaro, Carlos Oñate, Carmen Martín Algarra, Salvador Perez, Guiomar Landazuri, Sara F. Gonzalez, Alvaro Gross, Stefanie Rodriguez, Inmaculada Muñoz Calleja, Cecilia Rodríguez Ruiz, María Sangro, Bruno López Picazo, José M. Rizzo, Manglio Miguel Mazzolini Rizzo, Guillermo Daniel Pascual, Juan I. Andueza, Maria Pilar Perez Gracia, Jose Luis Melero, Ignacio |
author_role |
author |
author2 |
Carranza Rua, Omar Alfaro, Carlos Oñate, Carmen Martín Algarra, Salvador Perez, Guiomar Landazuri, Sara F. Gonzalez, Alvaro Gross, Stefanie Rodriguez, Inmaculada Muñoz Calleja, Cecilia Rodríguez Ruiz, María Sangro, Bruno López Picazo, José M. Rizzo, Manglio Miguel Mazzolini Rizzo, Guillermo Daniel Pascual, Juan I. Andueza, Maria Pilar Perez Gracia, Jose Luis Melero, Ignacio |
author2_role |
author author author author author author author author author author author author author author author author author author author |
dc.subject.none.fl_str_mv |
Il-8 Cancer Serum Levels Prognosis |
topic |
Il-8 Cancer Serum Levels Prognosis |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Purpose: Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. It exerts various functions in shaping protumoral vascularization and inflammation/immunity. We evaluated sequential levels of serum IL8 in preclinical tumor models and in patients to assess its ability to estimate tumor burden. Experimental Design: IL8 levelsweremonitored by sandwich ELISAs incultured tumor cells supernatants, tumor-xenograftedmice serum, and in samples from126 patients with cancer. Wecorrelated IL8 serumlevels with baseline tumor burden and with treatment-induced changes in tumor burden, as well as with prognosis. Results: IL8 concentrations correlated with the number of IL8-producing tumor cells in culture. In xenografted neoplasms, IL8 serum levels rapidly dropped after surgical excision, indicating an accurate correlation with tumor burden. In patients with melanoma (n = 16), renal cell carcinoma (RCC; n = 23), non-small cell lung cancer (NSCLC; n = 21), or hepatocellular carcinoma (HCC; n = 30), serum IL8 concentrations correlated with tumor burden and stage, survival (melanoma, n = 16; RCC, n = 23; HCC, n = 33), and objective responses to therapy, including those to BRAF inhibitors (melanoma, n = 16) and immunomodulatory monoclonal antibodies (melanoma, n = 8). IL8 concentrations in urine (n = 18) were mainly elevated in tumors with direct contact with the urinary tract. Conclusions: IL8 levels correlate with tumor burden in preclinical models and in patients with cancer. IL8 is a potentially useful biomarker to monitor changes in tumor burden following anticancer therapy, and has prognostic significance. Fil: Sanmamed, Miguel F.. Universidad de Navarra; España Fil: Carranza Rua, Omar. Universidad de Navarra; España Fil: Alfaro, Carlos. Universidad de Navarra; España Fil: Oñate, Carmen. Universidad de Navarra; España Fil: Martín Algarra, Salvador. Universidad de Navarra; España Fil: Perez, Guiomar. Universidad de Navarra; España Fil: Landazuri, Sara F.. Universidad de Navarra; España Fil: Gonzalez, Alvaro. Universidad de Navarra; España Fil: Gross, Stefanie. University Hospital Erlangen; Alemania Fil: Rodriguez, Inmaculada. Universidad de Navarra; España Fil: Muñoz Calleja, Cecilia. Universidad Autonoma de Madrid. Hospital Universitario de la Princesa; España Fil: Rodríguez Ruiz, María. Universidad de Navarra; España Fil: Sangro, Bruno. Universidad de Navarra; España Fil: López Picazo, José M.. Universidad de Navarra; España Fil: Rizzo, Manglio Miguel. Universidad Austral. Facultad de Ciencias Biomédicas. Laboratorio de Terapia Genética; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Laboratorio de Terapia Genética; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Pascual, Juan I.. Universidad de Navarra; España Fil: Andueza, Maria Pilar. Universidad de Navarra; España Fil: Perez Gracia, Jose Luis. Universidad de Navarra; España Fil: Melero, Ignacio. Universidad de Navarra; España |
description |
Purpose: Interleukin-8 (IL8) is a chemokine produced by malignant cells of multiple cancer types. It exerts various functions in shaping protumoral vascularization and inflammation/immunity. We evaluated sequential levels of serum IL8 in preclinical tumor models and in patients to assess its ability to estimate tumor burden. Experimental Design: IL8 levelsweremonitored by sandwich ELISAs incultured tumor cells supernatants, tumor-xenograftedmice serum, and in samples from126 patients with cancer. Wecorrelated IL8 serumlevels with baseline tumor burden and with treatment-induced changes in tumor burden, as well as with prognosis. Results: IL8 concentrations correlated with the number of IL8-producing tumor cells in culture. In xenografted neoplasms, IL8 serum levels rapidly dropped after surgical excision, indicating an accurate correlation with tumor burden. In patients with melanoma (n = 16), renal cell carcinoma (RCC; n = 23), non-small cell lung cancer (NSCLC; n = 21), or hepatocellular carcinoma (HCC; n = 30), serum IL8 concentrations correlated with tumor burden and stage, survival (melanoma, n = 16; RCC, n = 23; HCC, n = 33), and objective responses to therapy, including those to BRAF inhibitors (melanoma, n = 16) and immunomodulatory monoclonal antibodies (melanoma, n = 8). IL8 concentrations in urine (n = 18) were mainly elevated in tumors with direct contact with the urinary tract. Conclusions: IL8 levels correlate with tumor burden in preclinical models and in patients with cancer. IL8 is a potentially useful biomarker to monitor changes in tumor burden following anticancer therapy, and has prognostic significance. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-11 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/37046 Sanmamed, Miguel F.; Carranza Rua, Omar; Alfaro, Carlos; Oñate, Carmen; Martín Algarra, Salvador; et al.; Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins; American Association for Cancer Research; Clinical Cancer Research; 20; 22; 11-2014; 5697-5707 1078-0432 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/37046 |
identifier_str_mv |
Sanmamed, Miguel F.; Carranza Rua, Omar; Alfaro, Carlos; Oñate, Carmen; Martín Algarra, Salvador; et al.; Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins; American Association for Cancer Research; Clinical Cancer Research; 20; 22; 11-2014; 5697-5707 1078-0432 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/http://clincancerres.aacrjournals.org/content/20/22/5697.long info:eu-repo/semantics/altIdentifier/doi/10.1158/1078-0432.CCR-13-3203 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/msword application/pdf |
dc.publisher.none.fl_str_mv |
American Association for Cancer Research |
publisher.none.fl_str_mv |
American Association for Cancer Research |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613533095952384 |
score |
13.070432 |